FDA Oncology Trial Guidance Targets Eligibility Barriers

The new FDA oncology clinical trial eligibility guidance could change how sponsors decide who can enter cancer trials.

The three final guidances target performance status, washout periods and concomitant medications, and laboratory values, with a common objective to reduce unjustified exclusions while maintaining appropriate participant safety.

Regulatory note: These are FDA final guidance documents, not regulations. The FDA states that guidance represents its current thinking and is not legally binding unless incorporated into applicable requirements. 

Image

Why the FDA Is Reworking Oncology Eligibility Criteria

Clinical trial eligibility criteria serve an important purpose. They help sponsors define the study population and manage risks. However, criteria can become more restrictive than the study requires.

The U.S. Food and Drug Administration (FDA) released the three new guidances to address specific areas where this can occur.

Together, they encourage sponsors to ask a more fundamental question of whether an exclusion genuinely protects participants or simply reduces the eligible population?

The change also fits into the wider direction of Operation TrialBlazer, the HHS and FDA initiative to modernise clinical research and accelerate drug development. 

For sponsors, this is not simply an enrolment issue. Eligibility criteria influence recruitment speed, population diversity, protocol feasibility, and how representative trial evidence is of future patients.

Pharmatica’s analysis of clinical trial success rates highlights why every avoidable source of trial friction matters.

The guidance forms part of a broader FDA effort to improve clinical trial participation. The agency’s oncology guidance portfolio also includes earlier recommendations covering areas such as organ dysfunction, concurrent malignancies, and available therapy. 

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Performance Status Should Not Automatically Close The Door

Performance status is commonly used to describe how well a patient can perform everyday activities. It can help investigators assess whether someone is likely to tolerate a trial.

The new Performance Status guidance encourages consideration of broader performance-status eligibility where scientifically and clinically appropriate. 

The important point is that a patient’s status can reflect the effects of their cancer. It may not always represent a fixed measure of their ability to tolerate treatment.

For sponsors, this means performance status should be considered alongside disease characteristics, treatment objectives, safety considerations, and the potential for clinical improvement, rather than treated as an isolated exclusion mechanism.

Image

Washout Periods Need A Scientific Rationale

Washout periods can prevent interactions between previous medications or investigational treatments. They can also protect participants when residual effects from earlier therapies create genuine safety concerns.

But fixed time-based exclusions can also remove patients who might otherwise be suitable.

The FDA’s Washout and Concomitant Medications guidance recommends considering whether washout periods and medication exclusions are actually justified for a particular trial. 

This puts greater emphasis on the pharmacology and clinical context behind the exclusion, rather than applying a standard interval without sufficient rationale.

It could also reduce unnecessary protocol complexity. That matters when sponsors are competing for patients across increasingly crowded oncology trial landscapes.

Laboratory Thresholds Should Reflect Clinical Risk

Laboratory values are another common source of exclusion. Trials often specify minimum or maximum values for measures such as blood counts, renal function, or liver function.

The new Laboratory Values guidance recommends selecting laboratory criteria appropriately so that patients are not excluded without sufficient justification. 

The emphasis is therefore on scientific and safety relevance, rather than automatically adopting conservative thresholds.

This could be particularly important in oncology, where laboratory abnormalities may result from the underlying disease or previous treatment. A threshold that appears protective on paper may therefore exclude patients who could still participate safely.

FDA Oncology Clinical Trial Eligibility Guidance: What Sponsors Should Do Now

Oncology trial design is being pushed towards eligibility criteria that are more scientifically justified, more representative, and less restrictive where safety allows.

The three guidances should prompt sponsors to review eligibility criteria during protocol development, rather than waiting for recruitment problems to emerge.

A practical review should ask:

• Is every major exclusion supported by a clear safety or scientific rationale?
• Could a wider patient population answer the research question without increasing unacceptable risk?
• Are washout periods based on pharmacological evidence?
• Are laboratory thresholds clinically meaningful?
• Could broader eligibility improve recruitment and representativeness?

This is also where regulatory strategy and trial operations increasingly intersect. Sponsors that design more scientifically defensible criteria may improve recruitment without compromising the integrity of the study.

Pharmatica’s Operation TrialBlazer analysis examines the wider regulatory shift towards faster, more modern clinical development. Our CRO and vendor oversight analysis also explores how regulatory expectations increasingly translate into operational decisions.

At Pharmatica, we analyse how regulatory changes affect the real mechanics of pharmaceutical development, connecting FDA policy with clinical strategy, trial execution, and commercial implications. 

Pharmatica: Insight. Connection. Impact.

Image